180 Wealth Advisors’s Anavex Life Sciences AVXL Stock Holding History

180 Wealth Advisors’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$184K	Sell	71,030 -48,445	-41%	-$143K	0.02%	470
2026 Q1	$367K	Buy	119,475 +2,095	+2%	+$9.07K	0.04%	323
2025 Q4	$418K	Buy	117,380 +74,345	+173%	+$455K	0.05%	294
2025 Q3	$383K	Sell	43,035 -1,015	-2%	-$10.3K	0.05%	309
2025 Q2	$406K	Buy	44,050 +29,995	+213%	+$256K	0.06%	278
2025 Q1	$121K	Buy	+14,055	New	+$133K	0.02%	392

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

180 Wealth Advisors's AVXL Position: Q2 2026 in Review

180 Wealth Advisors reduced its Anavex Life Sciences (AVXL) stake by 41% in Q2 2026, selling an estimated $143K and leaving 71,030 shares worth $184K. The position accounts for 0.02% of the portfolio, ranked #470.

180 Wealth Advisors first reported a position in AVXL in Q1 2025 and has held it in 6 quarters since. The position peaked at $418K in Q4 2025. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

180 Wealth Advisors held 71,030 shares of Anavex Life Sciences worth $184K as of Q2 2026.
180 Wealth Advisors sold 48,445 Anavex Life Sciences shares in Q2 2026, an estimated $143K.
Anavex Life Sciences made up 0.02% of 180 Wealth Advisors's portfolio in Q2 2026, its #470 holding.
180 Wealth Advisors first reported a position in Anavex Life Sciences in Q1 2025 and has held it in 6 quarters since.
180 Wealth Advisors's Anavex Life Sciences position peaked at $418K in Q4 2025.
179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on 180 Wealth Advisors's 13F filing for Q2 2026, filed 7 Jul 2026.